CoTherix
From Wikipedia, the free encyclopedia
| CoTherix, Inc. | |
 |
|
| Type of Company | Public NASDAQ: CTRX |
|---|---|
| Founded | 2000 |
| Headquarters | Brisbane, California |
| Key people | Donald J. Santel, CEO & Director |
| Industry | Pharmaceutical |
| Products | Ventavis |
| Revenue | $23 million USD |
| Employees | 70 |
| Slogan | Developing and Commercializing New Therapies for Life-Threatening Diseases. |
| Website | www.cotherix.com |
CoTherix, Inc. is a biopharmaceutical company located in Brisbane, California. CoTherix focusses on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. The company,formerly known as Exhale Therapeutics, Inc., was founded in February 2000 by Gerard Turino, MD, a past president of the American Thoracic Society, and Jerome Cantor, MD, a pulmonary pathologist.
CoTherix's commercial product is "Ventavis (iloprost)", an inhaled therapy for pulmonary artery hypertension (PAH). It was approved by the United States Food and Drug Administration in December 2004, two months after the company's initial public offering of 5 millions shares of common stock.
CoTherix inlicensed Fasudil from Asahi Kasei in 2006 and has commercialization rights for it in the U.S. and Europe.
On November 20th 2006, CoTherix agreed to be purchased for $420 million in cash by Swiss-based Actelion. Under the deal, Actelion of Basel, Switzerland, will pay $13.50 for each share of CoTherix stock.
